Renée Aguiar-Lucander

Renée Aguiar-Lucander is an experienced health-care executive with a strong background in company management, financing and business development. She was recently appointed CEO of Hansa Biopharma, a Swedish company listed on OMX Stockholm. Previously, she was CEO of Calliditas Therapeutics AB, a Swedish NASDAQ traded company. Beginning in 2017, Ms. Aguiar-Lucander led that company’s development of a targeted release formulation of budesonide to full FDA approval in Dec 2023. Ms. Aguiar-Lucander grew Calliditas to a fully integrated life science company headquartered in Europe with a complete US commercial footprint. In Q3 2024, Calliditas was acquired by the Japanese Company Asahi Kasei for 1.1B USD and is now fully integrated into Asahi Kasei, with revenues in excess of USD 150 million and operational profitability at time of exit.   Prior to joining Calliditas, Ms. Aguiar-Lucander spent more than twenty years in US and European private and public direct investment, gaining experience with RAL Capital as non-executive director and Chairman in innovative private and public growth companies, with Positive Capital Partners in project based strategic and financing services, as a partner in Omega Fund, Partner in 3i Group plc and managing director and Group Head at Lehman Brothers. She has extensive Board experience across private and public enterprises in Europe and the US, and successfully raised over USD 325M through public listings in Europe and US, out-licensings and debt financings.   Ms. Aguiar-Lucander holds a BA in Accounting from the Stockholm School of Economics and Finance, and an MBA from INSEAD.